Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H28N2O5S |
| Molecular Weight | 468.565 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)C1=CC=C(CN(CC2=CC=CC(OCC(O)=O)=C2)S(=O)(=O)C3=CN=CC=C3)C=C1
InChI
InChIKey=WOHRHWDYFNWPNG-UHFFFAOYSA-N
InChI=1S/C25H28N2O5S/c1-25(2,3)21-11-9-19(10-12-21)16-27(33(30,31)23-8-5-13-26-15-23)17-20-6-4-7-22(14-20)32-18-24(28)29/h4-15H,16-18H2,1-3H3,(H,28,29)
Evatanepag (CP-533,536) is a prostaglandin E2 EP2 receptor agonist. It stimulates new bone formation on trabecular, endocortical, and periosteal surfaces and enhances fracture healing. Evatanepag was under development with Pfizer as a bone formation stimulant for therapeutic use in the healing of fractures.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. | 2009-04-01 |
|
| CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance. | 2008-10 |
|
| In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist. | 2008-01-16 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C78568
Created by
admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID20945000
Created by
admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
|
PRIMARY | |||
|
223488-57-1
Created by
admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
|
PRIMARY | |||
|
DB12022
Created by
admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
|
PRIMARY | |||
|
C83707
Created by
admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
|
PRIMARY | |||
|
300000034247
Created by
admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
|
PRIMARY | |||
|
9151
Created by
admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
|
PRIMARY | |||
|
9890801
Created by
admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
|
PRIMARY | |||
|
UU-103
Created by
admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
|
PRIMARY | |||
|
L266R6E31E
Created by
admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL563646
Created by
admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
